| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_deb880c2e2ee8035167473ba0e31e123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e9cdfed02e2c6891a7c7813abfd0e7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c2c470cb3c0e3557639526cb1442d9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f4199ca1b14e5c729ac8fa14efdc03d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e86f66ec035d6562452db2dab059d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1a6d29fff75939ee0f08e394a51bef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f4101301ae6817b9cdf3a7e390bd28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1dd1651890f70c07eaaa6ea6891d14 |
| publicationDate |
2016-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016102144-A1 |
| titleOfInvention |
Use of Reslizumab To Treat Moderate to Severe Eosinophilic Asthma |
| abstract |
Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL; and 2) administering to said patient a therapeutically effective dose of reslizumab. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018209308-A1 |
| priorityDate |
2014-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |